ESMO 2023 | Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: findings from clinical trials

Arun Azad, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of three clinical trials evaluating the efficacy of combining PARP inhibitors with androgen receptor pathway inhibitors (ARPis) for the treatment of patients with metastatic, castration-resistant prostate cancer. The trials discussed are the Phase III PROfound (NCT02987543) trial exploring abiraterone plus olaparib, PROpel (NCT03732820), Phase III MAGNITUDE (NCT03748641) exploring abiraterone plus niraparib and Phase III TALAPRO-2 (NCT03395197) exploring talazoparib plus enzalutamide. Dr Azad elaborates on the disease genotypes of patients who had the most profound responses to this type of combination therapy and the differences in findings between trials. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.